Talaris Therapeutics is a biotechnology business based in the US. Talaris Therapeutics shares (TALS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.00 – the same closing value as a week prior. Talaris Therapeutics employs 84 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $23.89 - $29.56 |
| 50-day moving average | $2.83 |
| 200-day moving average | $2.44 |
| Wall St. target price | $20.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.74 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0 from 2023-11-16
| 1 week (2024-09-23) | N/A |
|---|---|
| 1 month (2024-08-31) | N/A |
| 3 months (2024-06-30) | N/A |
| 6 months (2024-03-31) | N/A |
| 1 year (2023-10-04) | -100.00% |
|---|---|
| 2 years (2022-10-04) | -100.00% |
| 3 years (2021-10-04) | 14.63 |
| 5 years (2019-09-30) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -22.81% |
| Return on equity TTM | -41.64% |
| Profit margin | 0% |
| Book value | $34.88 |
| Market Capitalization | $119.6 million |
TTM: trailing 12 months
Talaris Therapeutics's shares were split on a 1:10 basis on 19 October 2023. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Talaris Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Talaris Therapeutics shares which in turn could have impacted Talaris Therapeutics's share price.
Over the last 12 months, Talaris Therapeutics's shares have ranged in value from as little as $23.8938 up to $29.5603. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Talaris Therapeutics's is 2.1789. This would suggest that Talaris Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Talaris Therapeutics's beta into context you can compare it against those of similar companies.
As of October 19, 2023, Talaris Therapeutics, Inc. was acquired by Tourmaline Bio, Inc. , in a reverse merger transaction. Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients.
Step 1: Open and fund your account, Step 2: Enable options trading, Step 3: Select and trade options, Step 4: Closing options trades.
Learn the basics of put options: what they are, how they work and a few examples.
Learn the basics of call options: what they are, how they work and examples.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
Check out the best-performing ETFs so far in 2024.
What to expect when you sign up for a Zacks Trade brokerage account.